Literature DB >> 9849380

Target volume definition for three-dimensional conformal radiation therapy of lung cancer.

J G Armstrong1.   

Abstract

Three-dimensional conformal radiation therapy (3DCRT) is a mode of high precision radiotherapy which has the potential to improve the therapeutic ratio of radiation therapy for locally advanced non-small cell lung cancer. The preliminary clinical experience with 3DCRT has been promising and justifies further endeavour to refine its clinical application and ultimately test its role in randomized trials. There are several steps to be taken before 3DCRT evolves into an effective single modality for the treatment of lung cancer and before it is effectively integrated with chemotherapy. This article addresses core issues in the process of target volume definition for the application of 3DCRT technology to lung cancer. The International Commission on Radiation Units and Measurements Report no. 50 definitions of target volumes are used to identify the factors influencing target volumes in lung cancer. The rationale for applying 3DCRT to lung cancer is based on the frequency of failure to eradicate gross tumour with conventional approaches. It may therefore be appropriate to ignore subclinical or microscopic extensions when designing a clinical target volume, thereby restricting target volume size and allowing dose escalation. When the clinical target volume is expanded to a planning target volume, an optimized margin would result in homogeneous irradiation to the highest dose feasible within normal tissue constraints. To arrive at such optimized margins, multiple factors, including data acquisition, data transfer, patient movement, treatment reproducibility, and internal organ and target volume motion, must be considered. These factors may vary significantly depending on technology and techniques, and published quantitative analyses are no substitute for meticulous attention to detail and audit of performance.

Entities:  

Mesh:

Year:  1998        PMID: 9849380     DOI: 10.1259/bjr.71.846.9849380

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  7 in total

Review 1.  Magnetic resonance imaging in lung: a review of its potential for radiotherapy.

Authors:  Shivani Kumar; Gary Liney; Robba Rai; Lois Holloway; Daniel Moses; Shalini K Vinod
Journal:  Br J Radiol       Date:  2016-02-03       Impact factor: 3.039

2.  Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume.

Authors:  Ernesto Brianzoni; Gloria Rossi; Sergio Ancidei; Alfonso Berbellini; Francesca Capoccetti; Carla Cidda; Paola D'Avenia; Sara Fattori; Gian Carlo Montini; Gianluca Valentini; Alfredo Proietti; Carlo Algranati
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-26       Impact factor: 9.236

3.  Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer.

Authors:  Ursula Nestle; Andrea Schaefer-Schuler; Stephanie Kremp; Andreas Groeschel; Dirk Hellwig; Christian Rübe; Carl-Martin Kirsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-10-21       Impact factor: 9.236

4.  Dynamic MR based analysis of tumor movement in upper and mid lobe localized lung cancer.

Authors:  A Kovacs; J Hadjiev; F Lakosi; G Antal; C Vandulek; E Somogyine Ezer; P Bogner; A Horvath; I Repa
Journal:  Pathol Oncol Res       Date:  2008-09-24       Impact factor: 3.201

5.  Conformal radiotherapy for lung cancer: interobservers' variability in the definition of gross tumor volume between radiologists and radiotherapists.

Authors:  Chiang J Tyng; Rubens Chojniak; Paula N V Pinto; Marcelle A Borba; Almir G V Bitencourt; Ricardo C Fogaroli; Douglas G Castro; Paulo E Novaes
Journal:  Radiat Oncol       Date:  2009-08-05       Impact factor: 3.481

Review 6.  Advances in radiation technology can improve survival and quality of life for cancer patients.

Authors:  J Armstrong
Journal:  Ir J Med Sci       Date:  2001 Jan-Mar       Impact factor: 2.089

7.  Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study.

Authors:  Bernd Gagel; Marc Piroth; Michael Pinkawa; Patrick Reinartz; Thomas Krohn; Hans J Kaiser; Sven Stanzel; Christian Breuer; Branka Asadpour; Axel Schmachtenberg; Michael J Eble
Journal:  BMC Cancer       Date:  2007-06-28       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.